Protocol Ledger

NCT05559164 · Phase II · RECRUITING

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Interventional Phase II clinical trial protocol NCT05559164 sponsored by Rutgers, The State University of New Jersey in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-19 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05559164
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05559164
Protocol FieldVerified Registry Value
NCT IdentifierNCT05559164
Consolidated Lead SponsorRutgers, The State University of New Jersey
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2022-09-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05559164
Hospital Research SiteLocationSite Profile
Rutgers Cancer Institute of New JerseyNew Brunswick, NJOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI